Free US stock insider buying and selling tracking with regulatory filing analysis for inside information on company health. We monitor corporate insider transactions because company officers often have the best understanding of their business prospects.
Ahead of its upcoming fiscal 2026 first-quarter earnings release, Regeneron Pharmaceuticals (NASDAQ: REGN) received a bullish rating update from TD Cowen, which lifted its 12-month price target 9.1% to $960 from $880 while reaffirming a Buy rating. The revision follows the U.S. FDA’s accelerated app
Regeneron Pharmaceuticals (REGN) - TD Cowen Ups Price Target Ahead of Fiscal Q1 Results, Supported by FDA Gene Therapy Approval - Revenue Beat
REGN - Stock Analysis
3993 Comments
1214 Likes
1
Everado
Registered User
2 hours ago
Great overview, especially the discussion on momentum and volume dynamics.
👍 191
Reply
2
Jersen
Consistent User
5 hours ago
Discover free US stock research tools, expert insights, and curated stock ideas designed to help investors navigate market volatility effectively. Our platform equips you with the same tools used by professional Wall Street analysts at a fraction of the cost. We provide technical analysis, fundamental research, sector comparisons, and valuation models for smart stock selection. Make smarter investment decisions with our comprehensive database and expert guidance designed for all experience levels.
👍 120
Reply
3
Genevea
Senior Contributor
1 day ago
This activated my inner expert for no reason.
👍 235
Reply
4
Maalik
New Visitor
1 day ago
This feels like a test I already failed.
👍 10
Reply
5
Kyona
Daily Reader
2 days ago
I’m reacting before my brain loads.
👍 161
Reply
© 2026 Market Analysis. All data is for informational purposes only.